Allergy Therapeutics Cash Flow Conversion Efficiency

Latest as of December 2025: -2.755x

Allergy Therapeutics cash flow conversion efficiency. Based on the latest financial reports, Allergy Therapeutics (AGY) has a cash flow conversion efficiency ratio of -2.755x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-11.71 Million ≈ $-1.42K USD) by net assets (GBX4.25 Million ≈ $516.98 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Allergy Therapeutics (2002–2025)

Cash flow conversion efficiency of Allergy Therapeutics from 2002 to 2025. This chart illustrates how Allergy Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Allergy Therapeutics stock price today for real-time trading data and today's change.

Allergy Therapeutics Cash Flow Conversion Ratio Explained

Allergy Therapeutics cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Allergy Therapeutics Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Allergy Therapeutics ranked by their cash flow conversion efficiency. Also see Allergy Therapeutics market cap and net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
SEALAND CAP. GA. LS-0001 F:7KM	N/A
Ampli SA w upadlosci ukladowej WAR:APL	0.049x
Rapid Nutrition PLC PA:ALRPD	-1.217x
Capital Gearing Trust LSE:CGT	0.006x
Brave Bison Group PLC LSE:BBSN	0.021x
Gentlemens Equity S.A. PA:MLGEQ	N/A
Global Energy Metals Corp V:GEMC	-0.028x
Venture Life Group PLC LSE:VLG	-0.012x

Annual Cash Flow Conversion Efficiency for Allergy Therapeutics (2002–2025)

The table below shows the annual cash flow conversion efficiency of Allergy Therapeutics from 2002 to 2025. Review AGY cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	GBX-28.19 Million ≈ $-3.43K	GBX-28.72 Million ≈ $-3.49K	1.019x	+111.76%
2024-06-30	GBX3.71 Million ≈ $451.28	GBX-32.14 Million ≈ $-3.91K	-8.665x	+42.10%
2023-06-30	GBX2.07 Million ≈ $251.37	GBX-30.92 Million ≈ $-3.76K	-14.964x	-3904.84%
2022-06-30	GBX37.77 Million ≈ $4.59K	GBX-14.11 Million ≈ $-1.72K	-0.374x	-312.95%
2021-06-30	GBX48.53 Million ≈ $5.91K	GBX8.52 Million ≈ $1.04K	0.175x	-37.42%
2020-06-30	GBX43.78 Million ≈ $5.33K	GBX12.28 Million ≈ $1.49K	0.280x	+88.05%
2019-06-30	GBX37.56 Million ≈ $4.57K	GBX5.60 Million ≈ $681.36	0.149x	+190.33%
2018-06-30	GBX23.03 Million ≈ $2.80K	GBX-3.80 Million ≈ $-462.59	-0.165x	-2878.67%
2017-06-30	GBX29.96 Million ≈ $3.65K	GBX178.00K ≈ $21.66	0.006x	+101.52%
2016-06-30	GBX30.32 Million ≈ $3.69K	GBX-11.84 Million ≈ $-1.44K	-0.390x	-530.91%
2015-06-30	GBX34.47 Million ≈ $4.19K	GBX3.12 Million ≈ $379.98	0.091x	-37.14%
2014-06-30	GBX15.07 Million ≈ $1.83K	GBX2.17 Million ≈ $264.39	0.144x	-13.04%
2013-06-30	GBX14.67 Million ≈ $1.79K	GBX2.43 Million ≈ $295.90	0.166x	-16.01%
2012-06-30	GBX14.59 Million ≈ $1.78K	GBX2.88 Million ≈ $350.41	0.197x	+120.83%
2011-06-30	GBX2.14 Million ≈ $260.25	GBX-2.03 Million ≈ $-246.63	-0.948x	-316.36%
2010-06-30	GBX3.89 Million ≈ $472.81	GBX1.70 Million ≈ $207.08	0.438x	+2206.97%
2009-06-30	GBX-23.18 Million ≈ $-2.82K	GBX-440.00K ≈ $-53.54	0.019x	-98.89%
2008-06-30	GBX-11.29 Million ≈ $-1.37K	GBX-19.32 Million ≈ $-2.35K	1.711x	+177.93%
2007-06-30	GBX8.60 Million ≈ $1.05K	GBX-18.88 Million ≈ $-2.30K	-2.196x	-786.27%
2006-06-30	GBX32.70 Million ≈ $3.98K	GBX-8.10 Million ≈ $-985.90	-0.248x	-8630.66%
2005-06-30	GBX20.08 Million ≈ $2.44K	GBX-57.00K ≈ $-6.94	-0.003x	-101.05%
2004-06-30	GBX7.08 Million ≈ $860.94	GBX1.91 Million ≈ $231.91	0.269x	-28.68%
2003-06-30	GBX5.55 Million ≈ $674.91	GBX2.10 Million ≈ $254.90	0.378x	-17.28%
2002-06-30	GBX-4.40 Million ≈ $-535.11	GBX-2.01 Million ≈ $-244.32	0.457x	--

About Allergy Therapeutics

LSE:AGY UK Drug Manufacturers - Specialty & Generic

Market Cap

$982.37K

GBX8.07 Billion GBX

Market Cap Rank

#30691 Global

#816 in UK

Share Price

GBX1.28

Change (1 day)

-1.92%

52-Week Range

GBX1.28 - GBX12.10

All Time High

GBX38.50